22:35 , May 17, 2019 |  BC Extra  |  Clinical News

May 17 Clinical Quick Takes: Achillion Phase III plans for PNH combo; plus NCI, MorphoSys

Achillion to start Phase III of PNH combo in 1H20  Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said it will start in 1H20 a Phase III trial evaluating oral CFD inhibitor ACH-4471 in combination with C5 inhibitors to...
21:51 , Feb 22, 2019 |  BioCentury  |  Emerging Company Profile

Gyroscope complements dry AMD

Gyroscope Therapeutics Ltd.’s complement-targeting gene therapy for dry age-related macular degeneration could have an edge over competing therapies that are dosed chronically or target complement downstream of its key immune mediators. On Feb. 19, Gyroscope...
19:26 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

Achillion discontinuing PNH monotherapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said it will discontinue development of ACH-4471 as oral monotherapy treatment of paroxysmal nocturnal hemoglobinuria in favor of an earlier stage compound. The decision is a delay for Achillion as it...
00:47 , Dec 19, 2018 |  BC Extra  |  Clinical News

Achillion down after discontinuing PNH monotherapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) lost $0.45 (19%) to $1.95 on Tuesday after it said it will discontinue development of ACH-4471 as oral monotherapy treatment of paroxysmal nocturnal hemoglobinuria in favor of an earlier stage compound....
21:52 , Jul 13, 2018 |  BioCentury  |  Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
21:23 , Feb 26, 2018 |  BC Extra  |  Company News

Achillion rises on positive opinion for C3G therapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said EMA's Committee for Orphan Medicinal Products issued a positive opinion recommending Orphan Drug designation for ACH-4471 to treat C3 glomerulopathy. Achillion gained $0.46 (15%) to $3.41 on Monday. ACH-4471 is...
20:35 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

Apellis reports 18-month Phase II data for GA candidate

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported 18-month data from the Phase II FILLY trial to treat geographic atrophy showing that APL-2 for 12 months maintained significant reductions in lesion growth at six months after stopping treatment....
22:56 , Feb 22, 2018 |  BC Extra  |  Clinical News

Apellis reports 18-month data for GA candidate

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported 18-month data from the Phase II FILLY trial to treat geographic atrophy showing that APL-2 for 12 months maintained significant reductions in lesion growth at six months after stopping treatment....
21:41 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Achillion reports preliminary data from a Phase II trial of ACH-4471 for C3 glomerulopathy

Achillion Pharmaceuticals Inc. (NASAQ:ACHN) said preliminary data from the first 2 patients in a Phase IIa trial to treat complement 3 (C3) glomerulopathy (C3G) showed ACH-4471 reduced albumin-to-creatinine ratio from baseline to day 17 by...
00:30 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

Genentech's lampalizumab misses in Phase III for geographic atrophy due to AMD

In September, the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported data from the Phase III Spectri (GX29185) trial in about 975 patients with geographic atrophy (GA) due to age-related macular degeneration (AMD) showing that...